Skip to main content

Table 2 Exploratory survival analysis

From: Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer

  b SE Wald dF Sig Exp(B)
(hazard ratio)
Base model
 Age 0.010 0.014 0.563 1 0.453 1.010
 Gender − 0.167 0.327 0.261 1 0.609 0.846
Incremental model: tumor M2-PK > 27 U/mL
 Age 0.004 0.015 0.076 1 0.782 1.004
 Gender − 0.221 0.329 0.452 1 0.501 0.802
Tumor M2-PK > 27 U/ml 0.718 0.353 4.132 1 0.042 2.049
Incremental model: Ca 19-9> 39
 Age 0.010 0.014 0.472 1 0.492 1.010
 Gender − 0.515 0.351 2.153 1 0.142 0.598
 Ca 19-9> 39 1.081 0.345 9.821 1 0.002 2.949
Incremental model: resection
 Age 0.013 0.014 0.862 1 0.353 1.013
 Gender − 0.233 0.330 0.501 1 0.479 0.792
 Resection − 0.632 0.326 3.744 1 0.053 0.532
Incremental model: staging
 Age 0.014 0.015 0.797 1 0.372 1.014
 Gender − 0.250 0.331 0.569 1 0.450 0.779
 Stage I − 1.191 0.628 3.594 1 0.058 0.304
 Stage II − 0.529 0.318 2.762 1 0.097 0.589
 Stage III + IV 0.635 0.308 4.261 1 0.039 1.888
  1. b regression coefficient, SE standard error of regression coefficient b. Wald Wald statistic (b/SE)2, Df degrees of freedom, Exp (B) hazard risk ratio
  2. The values in italics denote statistical significance